Kura Oncology Inc (KURA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $713.90M
Last updated: Nov 17, 2026 at 4:33 PM ET
Kura Oncology Inc (KURA) Statistics
Kura Oncology (KURA) has a market cap of $713.90M and an enterprise value of $665.79M. It kept -369.26% of revenue as net income over the last 12 months. Revenue fell 23.76% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 6.74% below the market cap, as cash exceeds debt.
| Market Cap | $713.90M |
|---|---|
| Enterprise Value | $665.79M |
| Latest price (Nov 17, 2026) | $7.49 |
Key Dates
The next earnings report is expected on Mar 3, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 3, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 8.5x and 37.5x. Its year-end P/S ranged from 13.5x to 875.7x from 2018 to 2025.
| P/S Ratio | 8.5x |
|---|---|
| Forward P/S | 7.6x |
| P/B Ratio | 37.5x |
Price Statistics
The stock is down 33.15% over 52 weeks and trades 24.72% below its 50-day average.
| Beta (1Y) | 1.36 |
|---|---|
| 52-Week Change | -33.15% |
| 1-Month Change | -19.98% |
| 3-Month Change | -40.22% |
| 6-Month Change | -16.41% |
| 5-Year Change | -37.52% |
| 10-Year Change | +153.33% |
| Total Return (1Y) | -33.15% |
| Total Return (3Y CAGR) | -7.81% |
| Total Return (5Y CAGR) | -15.38% |
| Return vs SPY (1Y) | -43.96% |
| Max Drawdown (1Y) | -49.96% |
| Max Drawdown (3Y) | -76.46% |
| Sharpe Ratio (1Y) | -0.61 |
| Correlation with SPY (1Y) | 0.29 |
| 50-Day Average | $9.95 |
| 200-Day Average | $9.77 |
| 52-Week Range | $6.75 to $13.90 |
| RSI (14 Days) | 37.4 |
| Average Volume (20 Days) | 2.47M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.60x current liabilities, and total debt is 0.55x shareholder equity.
| Current Ratio | 3.60x |
|---|---|
| Quick Ratio | 3.56x |
| Debt / Equity | 0.55x |
| Interest Coverage | -227.12x |
Returns and Efficiency
Return on invested capital is -1125.29% over the last 12 months, against a 5-year average of -81.01%.
| Return on Equity (ROE) | -1630.70% |
|---|---|
| Return on Assets (ROA) | -51.70% |
| Return on Invested Capital (ROIC) | -1125.29% |
| ROE (5Y Average) | -59.72% |
| ROA (5Y Average) | -29.77% |
| ROIC (5Y Average) | -81.01% |
| Asset Turnover | 0.13x |
| Inventory Turnover | 0.25x |
| Receivables Turnover | 6.63x |
| Cash Conversion Cycle | -542 days |
Scores
KURA has an Altman Z-Score of -3.55, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -3.55 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $79.31M over the last 12 months.
| Revenue | $79.31M |
|---|---|
| Revenue Growth (YoY) | -23.76% |
| Gross Profit | $78.38M |
| Operating Income | -$312.75M |
| Pretax Income | -$292.79M |
| Net Income | -$292.87M |
| Reported EPS (TTM) | -$3.30 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 3.17% of the $566.50M in total assets.
| Cash and Equivalents | $57.94M |
|---|---|
| Total Debt | $9.83M |
| Net Cash | $48.10M |
| Net Cash Per Share | $0.54 |
| Working Capital | $385.97M |
| Shareholder Equity | $17.96M |
| Book Value Per Share | $0.20 |
| Total Assets | $566.50M |
| Total Liabilities | $548.54M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $3.55M of capital spending, operating cash flow left -$89.12M of free cash flow.
| Operating Cash Flow | -$85.57M |
|---|---|
| Capital Expenditures | $3.55M |
| Free Cash Flow | -$89.12M |
| FCF Per Share | -$1.00 |
| Depreciation and Amortization | $4.68M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -394.32%.
| Gross Margin | 98.82% |
|---|---|
| Operating Margin | -394.32% |
| Pretax Margin | -369.15% |
| Net Margin | -369.26% |
| FCF Margin | -112.37% |
Growth
| Book Value Per Share Growth (2Y CAGR) | -37.95% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -37.95% |
Dividends and Yields
KURA does not pay a dividend. Its free cash flow yield is -13.25%.
| FCF Yield | -13.25% |
|---|---|
| Buyback Yield | -5.24% |
| Shareholder Yield | -5.24% |
Peer Position
Against 5 similar companies, KURA has the 3rd highest P/S.
P/S RatioPeer median 7.7x
ROICPeer median -25.72%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| P/S Ratio | 8.5x vs 7.7x median |
|---|---|
| ROIC | -1125.29% vs -25.72% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -23.76% vs -100.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 72.33% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +72.33% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About KURA
What is KURA's market cap?
Kura Oncology has a market cap of $713.90M. Its enterprise value, which adds debt and subtracts cash, is $665.79M.
How many shares of KURA are outstanding?
Kura Oncology has 89.82M shares outstanding. The count is up 2.48% from a year earlier.
Does KURA pay a dividend?
No. Kura Oncology does not pay a dividend.
How much debt does KURA have?
Kura Oncology has $9.83M of total debt and $57.94M of cash and equivalents, a net cash position of $48.10M.
KURA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors